

INDGN/SE/2025-26/88

December 31, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform that the Company's wholly owned subsidiaries, Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH have, on December 31, 2025, signed a Share Purchase Agreement ("SPA") to acquire 100% equity shares in Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)) ('Target Company'), wholly owned subsidiary of Trilogy Writing and Consulting GmbH.

Consequent to the above Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)) will cease to be the subsidiary of Trilogy Writing and Consulting GmbH and become the wholly owned subsidiary of Indegene, Inc.

The disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is mentioned in "Annexure-I".

The above information is being made available on the website of the Company at <https://www.indegene.com/>.

This is for your information and records.

Yours Sincerely,

For Indegene Limited

Srishti Ramesh Kaushik

Company Secretary and Compliance Officer



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040

Annexure-I

Sr. No.	Particulars	Description
1.	Name of the target entity, details in brief such as size, turnover etc.;	Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada) ("Trilogy Canada" or "Target Company") is a Canada-based company. Trilogy Canada specialises in medical writing. Trilogy Canada is incorporated in Canada. It reported turnover of CAD 892361.00 in its last financial year
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The transaction falls within related party transaction and no promoter / promoter group / group companies have any interest in the entity being acquired. The transaction is carried on an arm's length basis.
3.	Industry to which the entity being acquired belongs	Healthcare
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Internal restructuring
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable.
6.	Indicative time period for completion of the acquisition	31 December 2025
7.	Consideration – whether cash consideration or share swap or any other form and details of the same	cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	EUR 329,014.00
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country	Trilogy Canada specialises in medical writing. It has presence in Canada.

	<p>in which the acquired entity has presence and any other significant information (in brief)</p>	<p>Trilogy Canada is incorporated in Canada. It reported turnover of CAD 892361.00 in its last financial year.</p> <p>Date of incorporation: February 12, 2020</p> <p>Last 3 years turnover:</p> <table><tr><th>Turn over:</th><th>Amount in CAD</th></tr><tr><td>1 Jan 2022 - 31 Dec 2022</td><td>369636.00</td></tr><tr><td>1 Jan 2023 - 31 Dec 2023</td><td>505628.00</td></tr><tr><td>1 Jan 2024 - 31 Dec 2024</td><td>892361.00</td></tr></table>	Turn over:	Amount in CAD	1 Jan 2022 - 31 Dec 2022	369636.00	1 Jan 2023 - 31 Dec 2023	505628.00	1 Jan 2024 - 31 Dec 2024	892361.00
Turn over:	Amount in CAD									
1 Jan 2022 - 31 Dec 2022	369636.00									
1 Jan 2023 - 31 Dec 2023	505628.00									
1 Jan 2024 - 31 Dec 2024	892361.00									